HMPL-760 + HMPL-760 Placebo + R-GemOx
Phase 3Recruiting 0 watching 0 views this week๐ Rising
72
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Trial Timeline
Mar 10, 2026 โ Dec 30, 2028
NCT ID
NCT07409428About HMPL-760 + HMPL-760 Placebo + R-GemOx
HMPL-760 + HMPL-760 Placebo + R-GemOx is a phase 3 stage product being developed by HUTCHMED for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07409428. Target conditions include Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07409428 | Phase 3 | Recruiting |
Competing Products
20 competing products in Relapsed/Refractory Diffuse Large B-Cell Lymphoma